News|Articles|December 6, 2024
The Future of Cell Therapies
Author(s)Charles River
When complexities of developing donor-derived cell therapies are considered, NGS emerges clearly as a better, cost-effective yet regulatory-compliant solution.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
3
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
4
Charles River Incubator Cohort to Accelerate CGT Development
5
